Earnings call transcript: Oil-Dri posts record Q4 2026 results as shares fall

Oil-Dri reported record fiscal 2026 sales and net income, record EBITDA of $93 million, and Q4 revenue of $129.29 million with EPS of $1.00; operating cash flow was $80 million and year-end cash rose 45% to $74 million. Q4 B2B sales increased 4% to $50 million and retail and wholesale sales rose 3% to $79 million, while full-year fluids purification sales fell 5% and management cautioned Amlan’s exceptional Q4 pace may not continue. Shares fell 4.89% after hours to $80.25 despite the records. The company also expanded borrowing capacity across two facilities from $200 million to $375 million and said investment, dividends, acquisitions, and opportunistic repurchases remain capital priorities.

Analysis

The key issue is whether recent growth converts into durable earnings per share, not whether the year set records. Lightweight co-pack growth supports utilization and customer relevance, but undisclosed customer concentration and economics leave investors unable to underwrite the incremental return on dedicated capacity. Track volume, pricing, and capex returns; management’s claim of limited cannibalization is not independently verifiable from the disclosed data.

Near term, the after-hours selloff following a sharp prior run suggests a high bar for further upside: strong results without a measurable consensus beat or quantified forward outlook can trigger multiple compression. Gross margin holding flat despite freight pressure is encouraging, but delayed price actions and higher trucking costs make the next quarter a test of pass-through, not proof of sustained margin expansion. Amlan’s Q4 strength includes recovery from earlier account and tariff headwinds; extrapolating that run rate would overstate the signal. Brazil’s antibiotic restrictions are a structural demand catalyst, subject to registration, adoption, and competitive response.

Over 6–18 months, rising depreciation from recent investment and potential larger projects could absorb cash even as EBITDA grows. Expanded borrowing capacity is strategic optionality, not evidence of an impending acquisition; a poorly priced deal would undermine the balance-sheet premium. Agriculture growth also has exposure to planting cycles, while fluids purification remains volume-variable despite customer retention. The contrarian case is that the market may be discounting durable lightweight adoption and a healthier Amlan base—but the missing segment margins, co-pack concentration, and forward earnings bridge prevent a confident valuation-based call.

Key Decisions for Investors

• Do not chase the record-results headline. Treat ODC as a watchlist long until the next report confirms year-over-year growth excluding Amlan’s rebound effect and shows price realization offsetting freight costs.
• For an existing position, consider reducing exposure or hedging near-term event risk rather than assuming the post-earnings dip is a bargain; the prior run-up raises the risk of further multiple compression if growth normalizes.
• Monitor next-quarter gross margin, retail/wholesale operating income, Amlan growth versus the unusually strong Q4, and disclosed capex or capacity utilization. A margin decline or growth deceleration without offsetting guidance would falsify the durable-growth thesis.
• Reassess the long thesis if management provides evidence of sustained co-pack volume and attractive incremental returns; request customer concentration, segment profitability, and price-versus-volume data before underwriting a larger position.